

Published in final edited form as:

Bioorg Med Chem Lett. 2012 October 1; 22(19): 6229–6232. doi:10.1016/j.bmcl.2012.08.012.

2-Substituted 4,5-Dihydrothiazole-4-carboxylic Acids Are Novel Inhibitors of Metallo- β -lactamases

Pinhong Chen^a, Lori B. Horton^b, Rose L. Mikulski^a, Lisheng Deng^a, Sandeep Sundriyal^a, Timothy Palzkill^{a,b}, and Yongcheng Song^{a,*}

^aDepartment of Pharmacology, Baylor College of Medicine, 1 Baylor Plaza, Houston, Texas 77030, United States.

^bDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, 1 Baylor Plaza, Houston, Texas 77030, United States.

Abstract

Bacterial resistance to β -lactam antibiotics caused by class B metallo- β -lactamases (MBL), especially for certain hospital-acquired, Gram-negative pathogens, poses a significant threat to public health. We report several 2-substituted 4,5-dihydrothiazole-4-carboxylic acids to be novel MBL inhibitors. Structure activity relationship (SAR) and molecular modeling studies were performed and implications for further inhibitor design are discussed.

Keywords

Metallo- β -lactamase; Inhibitor; Rational design; Molecular modeling

The development of β -lactam antibiotics over the past 60 years has led to the availability of drugs to treat a wide range of Gram-positive and Gram-negative bacterial infections. However, during the past few decades, populations of drug resistant bacteria have increased significantly.¹ One important mechanism bacteria use to resist β -lactam antibiotics is the production of β -lactamases, which can hydrolyze the 4-membered β -lactam ring and render the drugs inactive. There are two mechanistically distinct types of β -lactamases: serine β -lactamases and metallo- β -lactamases (MBLs).² The class A, C and D β -lactamases belong to the first type and use a serine –OH group as a nucleophile to attack and hydrolyze the amide bond in the β -lactam ring. In contrast, the class B β -lactamases are Zn²⁺ dependent metalloenzymes, with one or two Zn ions at the active site.^{3,4} MBLs are able to hydrolyze essentially all β -lactams, including imipenem, which have the widest antibacterial spectrum and are one of the very few effective drugs to treat some Gram-negative bacterial infections, such as *Pseudomonas aeruginosa*. The clinical significance of these enzymes has only recently been recognized, when plasmid-encoded, transferable MBLs were found to spread quickly among many species of Gram-negative bacteria around the world and confer resistance to imipenem and extended-spectrum cephalosporins.^{5–7}

© 2012 Elsevier Ltd. All rights reserved.

*Corresponding author. Tel.: +1-713-798-7415; fax: +1-713-798-3145; ysong@bcm.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

dihydrothiazole-4-carboxylic acid, was found to be inactive. In addition, none of compounds **6** and **7** having a thiazolidine ring possess inhibitory activity against IMP-1.

We next synthesized compounds **8** – **13** shown in Table 2 to investigate the SAR for a substituent on the 2-phenyl ring of compound **4**. Compounds **8** and **9** with a 2-(4-chlorophenyl) and 2-(4-bromophenyl), respectively, were found to completely lose the inhibitory activity. Compound **10** with a 3-NH₂ substituent was observed to have a weak inhibitory activity with an IC₅₀ of 77.0 μM. Its derivatives **11** and **12** containing an additional acetyl and *tert*-butoxycarbonyl (BOC) group, respectively, are inactive. Compound **13** with a 2-OH substituent on the phenyl ring has also no activity. Compounds **14** – **17** (Table 2) were synthesized to find the effects of replacing 2-phenyl of **4** with an lipophilic amide or carbamate group. These groups were designed to mimic the sidechain of penicillin, one of the substrates of IMP-1. However, as can be seen in Table 2, none of these compounds show activity against IMP-1.

Molecular modeling (docking) was used to rationalize the above observed SARs. The crystal structure¹⁰ (PDB code: 1DD6) of IMP-1 in complex with the thiol inhibitor MCI (Figure 1) was chosen to be the docking template, which was prepared, according to our previous method,^{15,20,21} by removing only the inhibitor using the program Glide²² in Schrödinger (version 2010).²³ The two Zn²⁺ ions were treated as an integrated part of the protein. Compound **4** was built, energy-minimized using OPLS_2005 force field in Schrödinger, and docked into the prepared IMP-1 structure using Glide. Figure 3a shows the 20 docking structures of **4** with the lowest energies, which can be basically classified into two binding conformations A and B. Conformation A represents 7 tightly clustered docking structures with a lower average energy, and there are 13 docking poses in conformation B, as representatively shown in Figures 3b and 3c. The common feature of conformations A and B is that one O atom of the carboxylate group binds to both Zn²⁺ ions, behaving similarly as the S atom of MCI. The other O atom of **4** in conformation A also interacts with the tightly bound Zn1 (coordinated by three imidazoles of His77, 79 and 139), while that of B binds to the Zn2 (which is bound to IMP-1 via coordination by Asp81, Cys158 and His197 with less affinity). None of the N atoms of **4** in conformations A and B are predicted to bind to Zn²⁺, with the distances being >3 Å. It is of interest that the binding of the 2-phenyl group of **4** in conformations A and B is different. The phenyl of A is located almost in the same position as the phenyl of MCI, and the mainly hydrophobic pocket is tightly surrounded by Val25, Val31, Glu23 (the hydrophobic carbon skeleton), Ser21, Pro32, Phe51 and His197 (Figure 3b). The phenyl group of conformation B is situated in a much larger and longer channel that holds the two aromatic rings of MCI (Figure 3c). Our SAR results suggest the conformation A better mimics the real binding structure of compound **4** to IMP-1, because the pocket shown in Figure 3b could only accommodate a phenyl group favorably. Any additional substituent, even as small as a –Cl or –OH, could result in an unfavored steric and/or hydrophobic interaction. In addition, our SAR and docking studies could provide useful implications for future inhibitor design. For example, derivatives of compound **4** that possess an additional group that extends to the other binding site of IMP-1 could be more active.

Finally, we tested the inhibitory activities of newly synthesized compounds against another MBL, *Bacillus anthracis* Bla2,²⁴ in order to see whether our inhibitors have a broad spectrum of activity. *B. anthracis* is the causative agent of anthrax and expression of Bla2 can result in resistance to β-lactam antibiotics. Therefore, inhibitors of this enzyme have potential therapeutic value. The results are shown in Tables 1 and 2. Captopril was also found to be a weak inhibitor of Bla2 with an IC₅₀ value of 25.8 μM, or a K_i value of 17.9 μM, while EDTA is almost inactive against this enzyme (IC₅₀ > 1 mM). Although compound **4** is a good IMP-1 inhibitor, it was observed to have essentially no activity

against Bla2 with an IC₅₀ of >200 μM. However, analogous compound **10** with a 3-NH₂ substituent showed improved inhibitory activity against Bla2 as compared to captopril, with an IC₅₀ value of 4.9 μM (Table 2) or a K_i value of 5.1 μM. All other compounds, except for compound **12** being a weak inhibitor (IC₅₀ = 74.1 μM), are also inactive against Bla2. Nevertheless, the activity of compound **10** shows that it is also possible to develop 4,5-dihydrothiazole-4-carboxylic acids to find a compound that have a broad activity against other MBLs.

General methods for synthesizing compounds **3** – **17** are illustrated in Scheme 1.²⁵ For 4,5-dihydrothiazole compounds **3** – **5** and **8** – **13**, an aromatic nitrile, 1.2 equivalent amount of *L*-cysteine (or *D*-cysteine) hydrochloride and NaHCO₃ was refluxed in methanol and phosphate buffer (pH = 6) for 72h,²⁶ to give these compounds in 40 – 70% yield. However, this method does not work for making analogous compounds **14** – **17**. Rather, the methyl esters of these compounds were synthesized using a similar procedure,²⁷ which were carefully undergone a mild hydrolysis using 0.9 equivalent of LiOH to afford compounds **14** – **17** in 70 – 80% yield. Excess amount of LiOH caused decomposition of the products. Thiazolidine compounds **6** and **7** were prepared in ~80% yield by reacting benzaldehyde or phenylacetaldehyde with *L*-cysteine at room temperature in a mixture of ethanol and water.²⁸

In summary, this work is of interest for several reasons. First, using rational compound screening followed by medicinal chemistry, 2-phenyl-4,5-dihydrothiazole-4-carboxylic acid (**4**) was identified to be a novel inhibitor of *P. aeruginosa* MBL IMP-1 with an IC₅₀ value of 5.5 μM. Second, docking studies were explored to rationalize the structure activity relationships of this class of compounds and provide implications for future inhibitor design. Third, 2-(3-aminophenyl)-4,5-dihydrothiazole-4-carboxylic acid (**10**) was identified to be an inhibitor of *B. anthracis* MBL Bla2 (IC₅₀ = 4.9 μM), showing the promise of further developing this class of compounds in the context of overcoming β-lactam resistance.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by a grant (R21AI090190) from National Institute of Allergy and Infectious Disease (NIAID/NIH) to Y.S. and a grant (R01AI32956) from NIAID/NIH to T.P. L.B.H. was supported by a training grant (T90DK070109) from NIH/NIDDK.

References and notes

1. Leeb M. Nature. 2004; 431:892. [PubMed: 15496888]
2. Fisher JF, Meroueh SO, Mobashery S. Chem. Rev. 2005; 105:395. [PubMed: 15700950]
3. Crowder MW, Spencer J, Vila A. J. Acc. Chem. Res. 2006; 39:721.
4. Wang Z, Fast W, Valentine AM, Benkovic S. J. Curr. Opin. Chem. Biol. 1999; 3:614.
5. Walsh TR, Toleman MA, Poirel L, Nordmann P. Clin. Microbiol. Rev. 2005; 18:306. [PubMed: 15831827]
6. Bebrone C. Biochem. Pharmacol. 2007; 74:1686. [PubMed: 17597585]
7. Walsh TR. Clin. Microbiol. Infect. 2005; 11(Suppl 6):2. [PubMed: 16209700]
8. Toney JH, Moloughney JG. Curr. Opin. Investig. Drugs. 2004; 5:823.
9. Garcia-Saez I, Hopkins J, Papamicael C, Franceschini N, Amicosante G, Rossolini GM, Galleni M, Frere JM, Dideberg O. J. Biol. Chem. 2003; 278:23868. [PubMed: 12684522]

10. Concha NO, Janson CA, Rowling P, Pearson S, Cheever CA, Clarke BP, Lewis C, Galleni M, Frere JM, Payne DJ, Bateson JH, Abdel-Meguid SS. *Biochemistry*. 2000; 39:4288. [PubMed: 10757977]
11. Walter MW, Felici A, Galleni M, Soto RP, Adlington RM, Baldwin JE, Frère J-M, Gololobov M, Schofield C. J. *Bioorg. Med. Chem. Lett.* 1996; 6:2455.
12. Toney JH, Fitzgerald PM, Grover-Sharma N, Olson SH, May WJ, Sundelof JG, Vanderwall DE, Cleary KA, Grant SK, Wu JK, Kozarich JW, Pompliano DL, Hammond GG. *Chem. Biol.* 1998; 5:185. [PubMed: 9545432]
13. Toney JH, Hammond GG, Fitzgerald PM, Sharma N, Balkovec JM, Rouen GP, Olson SH, Hammond ML, Greenlee ML, Gao YD. *J. Biol. Chem.* 2001; 276:31913. [PubMed: 11390410]
14. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. *Antimicrob. Agents Chemother.* 1991; 35:147. [PubMed: 1901695]
15. Deng L, Sundriyal S, Rubio V, Shi Z, Song Y. *J. Med. Chem.* 2009; 52:6539. [PubMed: 19888756]
16. Jacobsen FE, Lewis JA, Cohen SM. *J. Am. Chem. Soc.* 2006; 128:3156. [PubMed: 16522091]
17. Jacobsen FE, Lewis JA, Cohen SM. *ChemMedChem.* 2007; 2:152. [PubMed: 17163561]
18. Brown NG, Horton LB, Huang W, Vongpunsawad S, Palzkill T. *Antimicrob. Agents Chemother.* 2011; 55:5696. [PubMed: 21896903]
19. The enzyme assay was performed using 2 nM IMP-1 (or 10 nM Bla2) and 25 μ M nitrocefin in 50 mM HEPES buffer (pH = 7.0) containing 20 μ g/mL BSA and 0.01% triton in a final volume of 300 μ L. For inhibition assay, compounds were pre-incubated with the enzyme for 20 min at room temperature, before initiation of the reaction by adding nitrocefin. The increasing absorbance at 482 nm was monitored using a Beckman DU640 UV spectrometer. The initial velocities for different concentrations of an inhibitor were imported into Prism (version 5.0, GraphPad, La Jolla, CA). The IC₅₀ as well as K_i values were calculated by using a standard dose response curve fitting in the software.
20. Deng L, Endo K, Kato M, Cheng G, Yajima S, Song Y. *ACS Med. Chem. Lett.* 2011; 2:165. [PubMed: 21379374]
21. Deng L, Diao J, Chen P, Pujari V, Yao Y, Cheng G, Crick DC, Prasad BVV, Song Y. *J. Med. Chem.* 2011; 54:4721. [PubMed: 21561155]
22. Glide, version 5.5. New York, NY: Schrödinger, LLC; 2010.
23. Schrödinger Suite, version 2010. New York, NY: Schrödinger, LLC; 2010.
24. Materon IC, Queenan AM, Koehler TM, Bush K, Palzkill T. *Antimicrob. Agents Chemother.* 2003; 47:2040. [PubMed: 12760895]
25. Experimental Section can be found in Supplemental Data on-line.
26. Lu Y, Li C, Wang Z, Chen J, Mohler ML, Li W, Dalton JT, Miller DD. *J. Med. Chem.* 2011; 54:4678. [PubMed: 21557538]
27. Merino P, Tejero T, Unzurrunzaga FJ, Franco S, Chiacchio U, Saita MG, Iannazzo D, Piperno A, Romeo G. *Tetrahedron Asymmetry.* 2005; 16:3865.
28. Lu Y, Li C, Wang Z, Ross CR, Chen J, Dalton JT, Li W, Miller DD. *J. Med. Chem.* 2009; 52:1701. [PubMed: 19243174]




Figure 1.
Representative MBL inhibitors.




Figure 2.
Structures of compounds 1 – 7.





Figure 3.

(A) Stereoview of the 20 lowest-energy docking structures of compound **4** in the active site of the crystal structure of IMP-1:MCI complex, with the protein shown as an electrostatic potential surface and Zn²⁺ as a light blue sphere; (B) The lowest-energy docking structure of conformation A of **4** (the ball and stick model in green) in the active site, superimposed with the crystal structure of MCI (in orange); (C) The lowest-energy docking structure of conformation B of **4** superimposed with the structure of MCI.

**Scheme 1.**

General synthesis for compounds **3 – 17.a**

^a*Reagents and conditions:* (i) NaHCO₃, phosphate buffer (pH = 6), MeOH, 66 °C, 72h; (ii) RCOCl or (BOC)₂O, Et₃N, CH₂Cl₂; (iii) *L*-Cys-OMe, Et₃N, MeOH; (iv) 0.9 equiv. 1 M LiOH, 0 °C – room temperature, 1h; (v) EtOH, H₂O, room temperature, 18h.

Table 1MBL inhibitory activities (IC₅₀ in μM) of **1** – **7**.

Compound	IC ₅₀ for IMP-1	IC ₅₀ for Bla2
Captopril	5.0	25.8
EDTA ^a	27.9	1060
1	34.7	>200
2	>200	>200
3	>200	>200
4	5.5	>200
5	>200	>200
6	>200	>200
7	>200	>200

^awith a 12-hour incubation.

Table 2Structures and activities of compounds **8 – 17**.

	R-	IC ₅₀ for IMP-1	IC ₅₀ for Bla2
8	4-Cl-phenyl	>200	>200
9	4-Br-phenyl	>200	>200
10	3-NH ₂ -phenyl	77.0	4.9
11	3-acetamido-phenyl	>200	>200
12	3-BOC _{NH} -phenyl	>200	74.1
13	2-OH-phenyl	>200	>200
14		>200	>200
15		>200	>200
16		>200	>200
17		>200	>200